BSI Launches New CE-Dedicated FastTrack Program
RESTON, VA. and PHILADELPHIA
BSI announced the launch of CE-Dedicated FastTrack. This new CE marking program is designed to help medical device manufacturers get their products quickly and safely to European markets. CE-Dedicated FastTrack offers reviews at an accelerated pace, within 45 working days or less. A key feature of the program is that BSI Product Experts dedicate a period of time to work exclusively with a particular client to complete the review, therefore travelling to the customer site is not required. CE-Dedicated leverages a range of communication technologies, paperless submissions and expertise that can quicken the review process to get new medical devices into the European market providing patients access to new technology.
CE-Dedicated is the fourth in a series of BSI Speed-to-Market Programs designed for Class III medical devices requiring CE marking design dossier reviews. Programs include: CE-90 standard, which completes most reviews within 90 working days from submission; CE-45 FastTrack, expedited reviews within 45 working days; and CE-Onsite FastTrack in which BSI Product Experts conduct reviews at the customer’s premises targeted at 45 working days.
“By utilizing high-tech capabilities, we provide a dynamic and personalized information interchange over geographic distances that streamline the entire review process,” states Ron Rakos, Vascular Team Leader, BSI Healthcare.
CE-Dedicated is not designed for all products, such as ones containing medicines, animal or blood derivatives that require the use of outside agencies and may not be eligible. Although BSI cannot guarantee a positive recommendation, the CE-Dedicated review provides manufacturers the benefit of knowing where they stand sooner in the process and a progress report for briefing upper management. The complexity of the product, timelines and regulatory requirements impact which program is best suited to the client’s needs. BSI works with clients to determine the right fit for each product.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
